Compass Pathways Expects to File COMP360 Application Within Two Weeks; Review Could Take 1-2 Months
Key Facts
Compass Pathways did not confirm in its public official announcement that it had completed filing the COMP360 application with the U.S. Food and Drug Administration, after saying on November 3 that the final submission was nearing completion and that it intended to file it within the following two weeks. That places the filing within a timeline disclosed by the company, but does not establish that the application had been sent by November 9. The application concerns the psilocybin drug the company is developing to treat treatment-resistant depression. The company said in April that the agency had authorized it to submit the application and review it in stages, and selected the drug for the National Priority Voucher program. Any accelerated review or commercial launch remains subject to subsequent regulatory steps.
Compass said the National Priority Voucher could shorten the review period to 1-2 months, presenting this as a possibility rather than a confirmed timetable for an agency decision. The estimate comes in the context of the staged review pathway that the company said the agency approved in April. The pathway allows sections of the application to be submitted and reviewed in sequence, according to the company's announcement of the agency's approval for a rolling review. The company says the voucher could reduce review time, but has not announced any guarantee that the application will be accepted or approved within that period. The timeline therefore remains the company's estimate tied to the application pathway, not a final regulatory decision.
The company bases its account of the program on what it said were positive results in two Phase 3 trials, as well as follow-up data from the COMP005 trial spanning 52 weeks. The open-label follow-up data showed, according to Compass, additional benefit after a further dose of 25 mg, with the effect extending to one year. In separate data announced by the company in September, the mean reduction from baseline on the MADRS scale was 13 points at week 52 among participants who received the additional dose. That was an open-label follow-up and therefore does not represent a comparison with a control group. The results provide indications of sustained benefit among participants under the follow-up design, but remain subject to the limitations of that design.
In the COMP006 trial, the company said in February that two doses of 25 mg met the primary endpoint, with a mean difference of 3.8 points in MADRS change compared with two doses of 1 mg at week six. Compass's figures link the higher dose with the improvement recorded in the trial. For the potential market, the company estimated that about 4 million people in the United States have treatment-resistant depression. It added that the only drug marketed for the condition had captured less than 3% of the market, describing the category as underserved. These are the company's market estimates, which place COMP360's development in the context of what it says is unmet patient need.
The company presented its cash balance as a factor supporting its funding plan: cash totaled $444 million at the end of the third quarter, on September 30, 2026. Compass said this balance provides funding beyond the expected launch and through 2028. In the market, the company's shares, listed under the ticker CMPS, closed at $8.61 on November 6. The closing price was from a session before the date of the news and does not in itself indicate investor reaction to completion of the filing. The next regulatory step remains submission of the final application, which the company said on November 3 it expects to file within the following two weeks.